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The prevalence of extended-spectrum -lactamase (ESBL)-producing Escherichia coli (ESBLEC) in Spain
increased 8-fold from 2000 to 2006. ESBL type, clonal relationship, antimicrobial susceptibility, and clinical
data about infections caused by ESBLEC are evaluated in a second nationwide study developed in 2006. From
1008 clinical isolates obtained over 2 months from 44 hospitals, 254 were used for further analysis. ESBL
production was evaluated by synergy testing, PCR, and sequencing. Antimicrobial activity was evaluated by
microdilution. The clonal relationship was evaluated by repetitive extragenic palindromic-PCR (REP-PCR).
The O25b subtype and the new afa operon FM955459 were determined by triplex PCR in isolates producing
CTX-M-15. Multilocus sequence typing was performed on these isolates. A total of 72% of all ESBLs were of
the CTX-M type, 26.8% were of the SHV type, and 1.2% were of the TEM type. The most prevalent ESBLs were
CTX-M-14 (119 isolates), SHV-12 (68 isolates), CTX-M-15 (37 isolates), and CTX-M-9 (21 isolates). By
REP-PCR, 214 clones were detected. All but five CTX-M-15 ESBLEC isolates corresponded to the international
O25b/ST131 clone. This clone had not been detected in the first study (published in 2000). Epidemiological and
clinical features were studied in 304 representative patients. A total of 60% of the patients were older than 60
and had nonfatal underlying diseases, and 55% had recently received antibiotics. Urinary tract infections
accounted for 71% of cases, and 9% were bacteremic. There has been a significant increase in the prevalence
of ESBLEC in Spain, with most of these strains being CTX-M-producing isolates, including the pandemic
O25b-ST131. SHV-12-producing E. coli remains an important cause of community-acquired infection.
Extended-spectrum -lactamase (ESBL)-producing Esche-
richia coli (ESBLEC) has emerged worldwide as a significant
cause of both community and healthcare-associated infections
(13). Moreover, the role of this microorganism as a cause of
nosocomial infection is also increasing (15). The type of ESBL
expressed by this microorganism has changed in recent years.
The classic SHV and TEM types have often been substituted
by members of the CTX-M family (3).
The epidemiology of ESBLEC is a complex and evolving
phenomenon. A few years ago most ESBLEC strains were
clonally unrelated, and the rapid emergence of ESBL was
related to the dissemination of mobile genetic elements (14).
Nevertheless, both plasmid and bacterial transmission between
humans has been demonstrated (17). Recently, the interna-
tional spread of the O25b-ST131 clone producing CTX-M-15
and other -lactamases has been described (6, 11). For these
reasons, the development of studies directed at discovering the
epidemiology of ESBLs in a specific area is recommended.
In 2000, the first nationwide study of ESBLEC was devel-
oped in Spain (GEIH-BLEE 2000) (8). The prevalence of
ESBL production among E. coli isolates was determined to be
0.5%, with CTX-M-9, SHV-12, and CTX-M-14 being the most
commonly found ESBLs. No CTX-M-15-producing E. coli
strain was isolated. A nationwide study designed along similar
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lines was developed in 2006 (GEIH-BLEE 2006) because of
perceived important changes in the epidemiology of ESBLEC.
In 6 years, the prevalence of ESBLEC increased to 4.04%
(range, 0.4 to 20.3%) in Spain (7). The distributions of origins
of infection between community-acquired, healthcare-associ-
ated, and nosocomial strains were 32, 36, and 30%, respec-
tively. The changes in ESBL type, clonal relationship, suscep-
tibility to antimicrobial agents, and relevant clinical data
pertaining to ESBLEC in Spain are discussed here.
MATERIALS AND METHODS
Bacterial isolates. Forty-four hospitals from all Spanish regions participated in
the GEIH-BLEE 2006 project. In the study period (from 1 February to 30 March
2006), 1,008 ESBLEC isolates were obtained from clinical samples (7). Identi-
fication of isolates to the species level was performed with the API 20E system
(bioMe´rieux, Marcy l’Etoile, France). ESBL production was confirmed by broth
microdilution according to CLSI guidelines (4). The first 254 ESBLEC isolates
were included for further microbiologic study.
Antimicrobial susceptibility testing. The MICs of cefotaxime (alone or with
clavulanic acid [4 mg/liter]), ceftazidime (alone or with clavulanic acid [4 mg/
liter]), cefepime, cefoxitin, cefotetan, imipenem, and meropenem were deter-
mined with MicroScan ESBL Plus ESBL confirmation panels (Siemens Health-
care Diagnostics, Sacramento, CA). In addition, broth microdilution using
Mueller-Hinton broth according to CLSI recommendations (5) was used to
determine susceptibility to the following antimicrobials: piperacillin (Sigma-Al-
drich, Madrid, Spain)-tazobactam (4 mg/liter, fixed concentration; Wyeth-Led-
erle, Madrid, Spain), amoxicillin (Sigma-Aldrich) and clavulanic acid (GSK,
Madrid, Spain) (amoxicillin-clavulanate proportion, 2:1), ertapenem (Merck,
Sharp, & Dohme, Madrid, Spain), amikacin (Sigma-Aldrich), gentamicin
(Sigma-Aldrich), tobramycin (Sigma-Aldrich), ciprofloxacin (Sigma-Aldrich),
cotrimoxazole (Sigma-Aldrich), tigecycline (Wyeth), and nitrofurantoin (Sigma-
Aldrich). E. coli ATCC 25922 and ATCC 35218 were used as control strains.
Molecular study. Clonal relationship of ESBL-producing strains was assessed
by repetitive extragenic palindromic-PCR (REP-PCR), as previously described
(14). Strains showing more than two different bands after electrophoresis of the
PCR product and ethidium bromide staining were considered unrelated. ESBL-
encoding genes were characterized by PCR using specific primers for TEM
(forward, 5-ATG AGT ATT CAA CAT TTC CG; reverse, 5-CTG ACA GTT
ACC AAT GCT TA), SHV (forward, 5-GGG TTA TTC TTA TTT GTC GC;
reverse, 5-TTA GCG TTG CCA GTG CTC), CTX-M-1 (forward, 5-GTT AAA
AAA TCA CTG CG; reverse, 5-CAT TCC GTT TCC GCT ATT AC; forward
2, 5-GCG GCC GCG CTA CAG TAC), and CTX-M-9 (forward, 5-GTG ACA
AAG AGA GTG CAA CGG; reverse, 5-ATG ATT CTC GCC GCT GAA
GCC) groups (8). Bacterial DNA was obtained by boiling a suspension of one or
two fresh colonies in distilled water for 10 min. Then, 10 l of supernatant was
added to a master mix containing PCR buffer (1), MgCl2 (2 mM), deoxynucleo-
side triphosphates (200 M), primer (0.5 M), and Taq polymerase (2 U). A
Techne TC-132 thermal cycler was used for amplification: a denaturation cycle of
4 min (95°C) was followed by 35 amplification cycles of 30 s (95°C), 30 s (58°C
for TEM/SHV, 62°C for CTX-M-9, and 60°C for CTX-M-1), and 1 min 15 s
(72°C), with a final extension cycle of 7 min (72°C). For sequencing the corre-
sponding ESBL-encoding gene, the products of specific ESBL-PCR were puri-
fied with the Real Clean Spin kit (Durviz) purification kit for direct sequencing.
ESBL sequences were developed in an external center (Newbiotechnic S.A.,
Seville, Spain) equipped with an ABI Prism 377 (Applied Biosystems/Perkin-
Elmer) sequencer. Sequences were analyzed by using the Chromas-Pro applica-
tion and BLAST Internet services (www.ncbi.nlm.nih.gov/BLAST). For CTX-M-
15-producing isolates, the O25b subtype and the presence of the new afa operon
FM955459 were determined by triplex PCR according to the method of Blanco
et al. (2). Furthermore, multilocus sequence typing (MLST) was used to confirm
that CTX-M-15-producing E. coli O25b belonged to the international clone
ST131 (11).
Epidemiological and clinical features. Epidemiological and clinical data from
a representative sample comprising 304 (30%) of all 1,008 patients in the study
were analyzed, a sample size that allowed us to performed comparisons in
subgroups according to acquisition. Cases included for analysis were chosen by a
random stratified procedure, using acquisition type and geographical area as the
stratification variables. Epidemiological and clinical features were collected by
using a structured questionnaire based on the following data: age, sex, healthcare
relation, underlying conditions, invasive procedures performed during the pre-
ceding week, antimicrobial use during the preceding month, type of infection,
and outcome. An ESBLEC was classified as nosocomially acquired (NA), health-
care associated (HCA), or community acquired (CA) according to the following
criteria: an ESBLEC isolate obtained 48 h after hospital admission was consid-
ered NA; of the rest, an ESBLEC isolate was considered HCA if the patient had
been admitted to an acute or long-term care center, received hemodialysis,
specialized home care, or day hospital care during the preceding 3 months.
Qualitative variables were compared by using the chi-square test or the Fisher
exact test, as appropriate. The study was approved by the Ethic Committee of the
participating centers.
RESULTS
Microbiological results. A total of 254 strains were charac-
terized. The antimicrobial susceptibility data of ESBL-produc-
ing strains are presented in Table 1. All of the strains included
in the present study were considered resistant to cefotaxime,
ceftazidime, cefpodoxime, cefepime, and aztreonam. We
found that 88 and 100% of E. coli isolates tested were suscep-
tible to cefoxitin and cefotetan, respectively. All isolates were
susceptible to imipenem, meropenem, ertapenem, and tigecy-
cline.
The most active -lactam/-lactamase inhibitor combination
against E. coli was piperacillin-tazobactam (88.6% susceptible
strains), followed by amoxicillin-clavulanic acid (69.3% suscep-
tible strains). The susceptibility percentages for other antimi-
crobials evaluated were as follows: 98%, amikacin; 78.3%, gen-
tamicin; 76%, tobramycin; 29.1%, ciprofloxacin; and 36.1%,
cotrimoxazole.
blaTEM, blaSHV, and blaCTX-M genes were detected by using
specific PCR in all cases. Of all identified ESBLs, 72% be-
longed to the CTX-M type, 26.8% belonged to the SHV type,
and 1.2% belonged to the TEM type. The most prevalent
ESBLs were CTX-M-14 (119 isolates), SHV-12 (68 isolates),
CTX-M-15 (37 isolates), and CTX-M-9 (21 isolates). All other
ESBLs were identified in five isolates or fewer (Fig. 1). Two
TABLE 1. In vitro activity of several antimicrobial
agents against ESBLEC
Agent
MIC (g/ml)
%Sa
Range MIC50 MIC90
Cefotaxime 8–128 128 128 0
Ceftazidime 0.5–128 64 128 0
Cefepime 1–32 32 32 0
Cefoxitin 2–32 4 16 88.2
Cefotetan 1–4 1 1 100
Amoxicillin-
clavulanate (2:1)
0.25–128 8 32 69.3
Piperacillin-
tazobactam
(4 g/ml)
0.5–64 4 32 88.6
Imipenem 0.5–1 0.5 0.5 100
Meropenem 0.5 0.5 0.5 100
Ertapenem 0.007–2 0.03 0.125 100
Amikacin 0.125–128 2 16 98
Gentamicin 0.06–128 0.5 64 78.3
Tobramycin 0.125–128 1 32 76
Ciprofloxacin 0.06–128 16 128 29.1
Cotrimoxazole 0.05/0.013–512/27 512/27 512/27 36.1
Tigecycline 0.06–2 0.125 0.25 100
Nitrofurantoin 2–512 16 64 87
a %S, the percent susceptibility determined according to CLSI guidelines (4).
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ESBLs were obtained in seven isolates, with the CTX-M-9 plus
SHV-12 combination (four isolates) being the most prevalent.
A total of 214 unrelated REP-PCR profiles were found; 7
profiles included two isolates each, and 1 profile included three
isolates. Isolates from these clusters came from a single hos-
pital, and no transmission between centers was detected. Fi-
nally, 32 of 37 isolates of CTX-M-15-producing E. coli were
determined to be positive by triplex PCR for the O25b molec-
ular subtype. All 32 O25b isolates were found by MLST to
belong to ST131, indicating that they all belonged to the in-
ternational clonal group O25b-ST131. These isolates were ob-
tained in 15 participating centers.
The geographical distribution of ESBLs in Spain is shown in
Fig. 1. Of note is the broad distribution of CTX-M-14, CTX-M
9, CTX-M-15, and SHV-12, found in several regions of Spain.
Epidemiological and clinical features. Of the 1,008 patients
included, the source of ESBLEC acquisition was classified as
NA in 312 (31%) cases, HCA in 363 (36%) cases, and CA in
333 (33%) cases. As explained in Materials and Methods, we
further analyzed the data of 304 representative patients. Apart
from the source of acquisition and the geographical area, these
patients showed no significant differences with regard to the
total population in terms of age distribution, gender, and sam-
ple yielding ESBLEC (data not shown). The features of the
patients according to origin of acquisition are shown in Table
2. Of the 112 patients with healthcare-associated ESBLEC, 17
(15%) were nursing home residents and 18 (16%) transplant
recipient patients. The majority of these patients were more
than 60 years old. Diabetes mellitus and recurrent urinary tract
infections were the most common underlying conditions. Com-
munity-acquired cases more frequently had a nonfatal under-
lying condition. Previous receipt of antimicrobials (particularly
fluoroquinolones) was common, more significantly for patients
with nosocomial and healthcare-associated infections. The
most common source of infection was the urinary tract; 52 of
the 215 (24%) urinary tract infection episodes were asymptom-
atic bacteriuria; 10 of the 25 episodes of intra-abdominal in-
fections were biliary tract infections, and 8 of the 15 respiratory
tract infections were pneumonia (7 being nosocomially ac-
quired). Overall, bacteremia (either primary or secondary) oc-
curred in 27 (9%) cases, and 16 cases (5%) were classified as
surgical-site infections. Crude mortality was 9% (27 patients).
Types of ESBLs produced by isolates from patients with NA,
HCA, and CA ESBLEC were similar (data not shown).
DISCUSSION
The prevalence and epidemiology of ESBLEC is changing
very rapidly in several countries (13). CTX-M is currently the
most prevalent ESBL family, particularly in community-ac-
quired infections (16). Nevertheless, other ESBLs, such as
SHV-12, are also relevant in the community (18). Further-
more, specific clones, such as the CTX-M-15-producing O25b-
ST131 clone, have emerged and been disseminated on differ-
ent continents. This clone has recently been described as
present in different areas in Spain (2, 12) and, to monitor the
FIG. 1. Distribution of ESBLEC isolates in Spain. (Modified from reference 8.)
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phenomenon in Spain, a second prevalence study was devel-
oped, one similar in design to that carried out in 2000. The
prevalence of ESBLEC in Spain has increased 8-fold, from
0.5% in 2000 to 4.04% in 2006 (7). In 2006, the incidence of
infections caused by ESBLEC ranged from 0.12 to 12.0/
100,000 population/month. This increase has been even greater
in other European countries (6).
In terms of antimicrobial resistance, there have been no
major relevant changes in ESBLEC between 2000 and 2006.
The most active antimicrobial agents against ESBLEC were
carbapenems, cefotetan, and tigecycline (the latter was not
included in the first survey), followed by amikacin. The actual
mechanisms involved in the higher activity of cefotetan in
comparison with cefoxitin have not been investigated specifi-
cally but could be related to altered permeability or increased
efflux affecting the two cephamycins in different ways. Cipro-
floxacin susceptibility decreased from 37.5% in 2000 to 29.1%
in 2006. This fact could be partially due to the dissemination of
the international clone O25b-ST131, which is resistant to cip-
rofloxacin. Besides chromosomal quinolone resistance mecha-
nisms, isolates belonging to this clone commonly expressed the
enzyme Aac(6)-lb-cr that affects susceptibility to ciprofloxacin
and some other fluoroquinolones, increasing their MIC values.
Among the -lactam/-lactamase inhibitor combinations, pip-
eracillin-tazobactam continues to be the most active agent
against this microorganism, probably due to the higher intrin-
sic activity of piperacillin compared to amoxicillin. The poten-
tial use of these combinations in infections caused by ESBLEC
is still controversial (9).
A molecular study of the selected strains in the present study
revealed important differences between the two periods eval-
uated. In 2000, a highly diverse population structure was ob-
served with a low clonal relationship among ESBLEC strains
(170 strains/137 clones), even for those isolated in the same
institution (8). In only three centers did more than one E. coli
isolate (n  2 to 14) present the same REP-PCR pattern. In
TABLE 2. Features of 304 selected patients with ESBLC
Parameter
No. of patients (%) with ESBLEC
Total
(n  304)
Community-acquired
(n  99)a
Healthcare associated
(n  112)b
Nosocomially acquired
(n  93)
Age (yr)
15 16 (5) 9 (9)† 2 (2) 5 (5)
15–60 98 (32) 29 (20) 37 (33) 32 (34)
60 190 (63) 61 (62) 73 (65) 56 (60)
Males 124 (41) 32 (32)‡ 47 (42) 45 (48)
McCabe classification
Nonfatal 204 (67) 79 (80)†‡ 71 (63) 54 (58)
Ultimately fatal 90 (30) 19 (19)‡ 37 (33) 34 (37)
Rapidly fatal 10 (3) 1 (1) 4 (4) 5 (5)
Underlying conditions
Diabetes mellitus 61 (20) 16 (16)† 35 (31)* 10 (11)
Chronic renal insufficiency 26 (9) 2 (2)†‡ 14 (13) 10 (11)
Chronic pulmonary disease 40 (13) 8 (8)† 17 (15) 15 (16)
Solid cancer 32 (11) 5 (5) 15 (13) 12 (13)
Hematologic cancer 11 (4) 0‡ 4 (4) 7 (8)
Liver cirrhosis 10 (3) 0‡ 4 (4) 6 (7)
Urinary tract structural disease 39 (13) 9 (9)‡ 24 (21)* 6 (7)
Recurrent urinary tract infection 63 (21) 21 (21) 36 (32)* 6 (7)
Invasive procedures
Urinary catheter 94 (31) 8 (8)†‡ 26 (23)* 60 (64)
Vascular catheter 76 (25) 0†‡ 14 (13)* 56 (60)
Mechanical ventilation 23 (8) 0‡ 0* 19 (20)
Previous antimicrobials 166 (55) 35 (35)†‡ 71 (63) 60 (65)
Fluoroquinolones 80 (26) 13 (13)†‡ 37 (33) 30 (32)
Oxyimino -lactams 46 (16) 7 (7)†‡ 19 (17) 20 (22)
Amoxicillin-clavulanate 46 (15) 8 (8)‡ 19 (17) 19 (20)
Types of infection
Urinary tract infection 215 (71) 70 (80)‡ 88 (79) 48 (52)
Skin and soft tissue infection 26 (9) 4 (4)‡ 9 (8) 13 (14)
Intra-abdominal infection 25 (8) 10 (10) 5 (5) 10 (11)
Respiratory tract infection 15 (5) 1 (1)‡ 2 (2)* 12 (13)
Primary bacteremia 15 (5) 2 (2) 6 (5) 7 (8)
Others 8 (3) 2 (2) 3 (3) 3 (3)
a †, P  0.05 for comparisons between community-acquired and healthcare-associated cases; ‡, P  0.05 for comparisons between community-acquired and
nosocomially acquired cases.
b , P  0.05 for comparison between healthcare-associated and nosocomially acquired cases.
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2006, a similar situation was observed, except for the dissem-
ination of CTX-M-15-producing E. coli O25b-ST131, isolated
in 15 different centers.
The ESBL type has also changed very rapidly. TEM-type-
producing E. coli have decreased very rapidly in Spain from
2000 (19%) to 2006 (1.2%). Ten different TEM-type ESBLs
were detected in 88 ESBLEC strains isolated in 2000. In the
present study, only TEM-4 and TEM-52 were detected in a
total of three isolates. Nevertheless, the prevalence and vari-
ability of the CTX-M-type ESBL have increased in E. coli from
52 to 72% in 6 years. CTX-M-14 remains the most prevalent,
followed by CTX-M-15 (not found in the first nationwide
study) and then CTX-M-9. It has been pointed out that in this
short period of time, the O25b-ST131 clone producing CTX-
M-15 was introduced and disseminated in Spain, as described
for other countries (6, 11). CTX-M-15-producing ESBLEC
was not confined to northern regions, and some local studies
on clinical isolates obtained after 2006 have also detected an
increase in these strains, particularly the international clone
O25b-ST131, in the northwest of Spain (2). Whether the
spread of this international clone will displace other clones in
the future remains uncertain, although local data point to this
hypothesis (2, 10).
The percentage of the SHV-type ESBL remains similar in
both studies. Nevertheless, the proportion of SHV-12 in-
creased in the 2006 study. Our group has remarked on the
important role of SHV-12-producing E. coli as a cause of
infection in the community, which has probably been underes-
timated as a consequence of the worldwide CTX-M explosion
(18). In a similar study developed in 2006 in the French com-
munity setting, the percentage of CTX-M-producing ESBLEC
was much higher (83%). SHV-12 was expressed only in 1 of 48
isolates (1).
ESBL distribution in Spain is different from that observed
in other countries, underlining the great epidemiological
variability of these resistance determinants and the need to
study them under different epidemiological conditions. Nev-
ertheless, the dissemination of the O25b-ST131 clone pro-
ducing CTX-M-15 seems to be very similar in different Eu-
ropean countries (1, 11).
In contrast to many other studies of ESBL-producing organ-
isms in different countries, in which only microbiological as-
pects have usually been considered, we have been able to
include, in this analytical study, epidemiologic and clinical fea-
tures of ESBLEC patients. We cannot make comparisons with
the 2000 study since the earlier one did not include such in-
formation. However, the data from the present study show
largely similar results to a previous multicenter study in Spain
performed during 2002 and 2003, evaluating community-onset
infections due to ESBLEC (16), but with one significant dif-
ference: the percentage of patients coming from nursing
homes doubled from 7% of patients with healthcare-associated
infections to 15%. This might be related to the incipient spread
in Spain of strains of the international O25b-ST131 clone pro-
ducing CTX-M-15, which has been found to reside in nursing
homes in Spain (2, 12) and other countries (19).
In summary, the present study emphasizes the significant
increase in ESBLEC in Spain over a 6-year period. Although
there was great variability in terms of clones and ESBL types,
most were CTX-M-producing E. coli, including the pandemic
CTX-M-15-producing clone O25b-ST131. It is also remarkable
that SHV-12-producing E. coli remains an important cause of
community-acquired infections.
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